Truist Financial Corp Sells 6,423 Shares of DaVita Inc. (NYSE:DVA)

Truist Financial Corp decreased its stake in shares of DaVita Inc. (NYSE:DVA) by 56.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,042 shares of the company’s stock after selling 6,423 shares during the period. Truist Financial Corp’s holdings in DaVita were worth $754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after buying an additional 154,061 shares during the period. Glenmede Trust Co. NA lifted its holdings in DaVita by 731.6% in the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after acquiring an additional 108,446 shares during the period. JPMorgan Chase & Co. boosted its position in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. KBC Group NV grew its stake in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares during the period. Finally, Strategic Financial Concepts LLC purchased a new stake in shares of DaVita during the 4th quarter valued at about $9,371,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $147.83 on Monday. The company has a market capitalization of $11.83 billion, a P/E ratio of 13.76, a P/E/G ratio of 1.07 and a beta of 0.94. DaVita Inc. has a 1-year low of $124.70 and a 1-year high of $179.60. The firm’s 50 day simple moving average is $160.66 and its two-hundred day simple moving average is $158.23. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on DVA shares. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.